Vaxcyte Revenue and Competitors
Estimated Revenue & Valuation
- Vaxcyte's estimated annual revenue is currently $17.1M per year.
- Vaxcyte's estimated revenue per employee is $52,786
- Vaxcyte's total funding is $281M.
- Vaxcyte's current valuation is $1B. (January 2022)
Employee Data
- Vaxcyte has 323 Employees.
- Vaxcyte grew their employee count by 54% last year.
Vaxcyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, General Counsel and Corporate Secretary | Reveal Email/Phone |
2 | SVP, Nonclinical, Clinical Serology, Immunoassays | Reveal Email/Phone |
3 | VP Corporate Communications & Investor Relations | Reveal Email/Phone |
4 | VP Analytical Development and QC | Reveal Email/Phone |
5 | Executive Assistant To CEO and Chief Financial Officer/President | Reveal Email/Phone |
6 | VP, IT and Facilities | Reveal Email/Phone |
7 | VP Research and Founder | Reveal Email/Phone |
8 | SVP, Development and Manufacturing | Reveal Email/Phone |
9 | Project Director, Program Management | Reveal Email/Phone |
10 | Executive Director Quality Assurance | Reveal Email/Phone |
Vaxcyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Vaxcyte?
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company's cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte's proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
keywords:N/A
$281M
Total Funding
323
Number of Employees
$17.1M
Revenue (est)
54%
Employee Growth %
$1B
Valuation
N/A
Accelerator
Vaxcyte News
Vaxcyte, Inc. (NASDAQ:PCVX Get Rating) COO Jim Wassil sold 2,800 shares of the stock in a transaction that occurred on Monday, April 18th.
Get Vaxcyte alerts: On Monday, March 21st, Grant Pickering sold 14,288 shares of Vaxcyte stock. The stock was sold at...
SAN CARLOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Other Companies in Foster City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $71M | 327 | 16% | $384.5M |
#2 | $116.1M | 379 | N/A | N/A |
#3 | $79.5M | 424 | 5% | N/A |
#4 | $143.3M | 468 | 8% | N/A |
#5 | $90M | 506 | -1% | $61.9M |